Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fmolb.2015.00027 http://scihub22266oqcxt.onion/10.3389/fmolb.2015.00027 C4440380!4440380!26052517     free     free     free       Front+Mol+Biosci 2015 ; 2 (ä): ä Nephropedia Template TP {{tp|p=26052517|t=2015. Evolution and intelligent design in drug development |pdf=|usr=}}{{26052517}} gab.com Text Evolution and intelligent design in drug development JO: Front Mol Biosci http://www.kidney.de/pget.php?&tw=1&pmid=26052517 #FOAvip Sophisticated protein kinase networks, empowering complexity in higher organisms, are also drivers of devastating diseases such as cancer. Accordingly, these enzymes have become major drug targets of the twenty-first century. However, the holy grail of designing specific kinase inhibitors aimed at specific cancers has not been found. Can new approaches in cancer drug design help win the battle with this multi-faced and quickly evolving enemy? In this perspective we discuss new strategies and ideas that were born out of a recent breakthrough in understanding the molecular basis underlying the clinical success of the cancer drug Gleevec. An ?old? method, stopped-flow kinetics, combined with old enzymes, the ancestors dating back up to about billion years, provides an unexpected outlook for future intelligent design of drugs. Twit Text FOAVip Evolution and intelligent design in drug development ????Front Mol Biosci http://www.kidney.de/pget.php?&tw=1&pmid=26052517 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26052517 #FOAvip English Wikipedia <ref>{{Cite pmid|26052517}}</ref> Evolution and intelligent design in drug development #MMPMID26052517 Agafonov RV; Wilson C; Kern D Front Mol Biosci 2015[]; 2 (ä): ä PMID26052517show ga Sophisticated protein kinase networks, empowering complexity in higher organisms, are also drivers of devastating diseases such as cancer. Accordingly, these enzymes have become major drug targets of the twenty-first century. However, the holy grail of designing specific kinase inhibitors aimed at specific cancers has not been found. Can new approaches in cancer drug design help win the battle with this multi-faced and quickly evolving enemy? In this perspective we discuss new strategies and ideas that were born out of a recent breakthrough in understanding the molecular basis underlying the clinical success of the cancer drug Gleevec. An ?old? method, stopped-flow kinetics, combined with old enzymes, the ancestors dating back up to about billion years, provides an unexpected outlook for future intelligent design of drugs. äEvolution and intelligent design in drug development (epmc).pdf DeepDyve Pubget Overpricing